News and Updates from the American Society of Clinical Oncology Annual Meeting
For the physicians treating men with non-metastatic castration resistant prostate cancer, knowing the risk of progression or death provides valuable information to guide the timing and selection of treatment.
Physicians and patients want to do everything possible to minimize the risk of breast cancer recurrence without incurring unnecessary toxicity from chemotherapy.
While guidelines for multiple myeloma advise pharmacologic prophylaxis to prevent development of venous thromboembolism (VTE) in high-risk patients, current risk assessment tools differ in the factors considered indicative of high risk and in the patients determined to need preventive anticoagulation.
Multiple organizations have recommended timely treatment for patients with lung cancer.
The treatment armamentarium for renal cell carcinoma and other genitourinary cancers continues to expand.
More than 95,000 Americans develop colon cancer, making it the third most common cancer in the U.S., excluding skin cancers.
Accounting for nearly a third of all cancer diagnoses, prostate cancer is the most frequently diagnosed cancer in the VHA, where past research has suggested that the malignancy is caught earlier than in other healthcare systems.
In the past five years, 10 new system therapies have been approved for renal cell carcinoma (RCC), the most common type of kidney cancer.
In the last decade, the development of multiple molecular-targeted therapies has dramatically altered the treatment landscape for advanced renal cell carcinoma (RCC).
The most common age for diagnosis of schizophrenia is late teens to early 30s.
Some of the risks of diabetic foot ulcers (DFUs) are well-known, including infection and, in the most severe cases, amputation.
© 2000-2018. All Materials Copyright Marathon Medical Communications, Inc.